{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-161600","form_type":"8-K","ticker":"KRRO","cik":"0001703647","company_name":"Korro Bio, Inc.","filed_at":"2023-06-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.119362+00:00","generated_at":"2026-06-14T06:41:47.708027+00:00","sec_items":["2.05","5.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Frequency Therapeutics cuts workforce by 55%, extends CFO severance terms","bullets":["Workforce reduction of approximately 55%; severance costs estimated at $1.16M.","Reduction to be completed by June 9, 2023; Board approved May 31, 2023.","CFO Richard Mitrano's severance extended: non-CIC from 6 to 9 months, CIC from 9 to 12 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-161600","json":"https://secwatch.observer/filing/0001193125-23-161600.json","markdown":"https://secwatch.observer/filing/0001193125-23-161600.md","text":"https://secwatch.observer/filing/0001193125-23-161600.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703647/000119312523161600/0001193125-23-161600-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703647/000119312523161600/d390817d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T06:41:47.708027+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c12141b7c541b41cbbe0f6b26313e59cdc23d674","claim":"Korro Bio, Inc. announced a restructuring with charges of approximately $1.16 million (approximately 55% of its workforce).","evidence_excerpt":"On May 31, 2023, Frequency Therapeutics, Inc. (the “Company”) announced a reduction in force (the “Reduction”) of approximately 55% of its workforce. The purpose of the Reduction, which was approved by the Board of Directors (the “Board”) of the Company on May 31, 2023, is to better align the Company’s workforce with the changing needs of its business. The Reduction will be completed by June 9, 2023. The total costs related to the Reduction are estimated to be approximately $1.16 million in future cash outlays primarily related to severance costs and related expenses.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312523161600/0001193125-23-161600-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $1.16 million"},{"label":"Headcount","value":"approximately 55% of its workforce"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}